CA125在卵巢癌诊断中的应用困境与突破  

Obstacles and breakthroughs in application of CA125 to ovarian cancer diagnosis

作　　者：徐丛剑[1] 王宜生[1] 杨子健[1] 

机构地区：[1]复旦大学附属妇产科医院,上海200011

出　　处：《中国实用妇科与产科杂志》2016年第5期417-421,共5页Chinese Journal of Practical Gynecology and Obstetrics

摘　　要：CA125是应用最广泛的卵巢癌血清标志物。但近年来发现其诊断特异度较低,不少良性疾病患者及妊娠期或月经期妇女血清CA125也明显升高。这一状况给卵巢癌术前诊断及人群筛查带来诸多困扰。鉴于CA125分子是一种高度糖基化的黏蛋白,其糖基化修饰在卵巢癌中具有明显的特征结构,近期研究证实被特征性糖链所修饰的CA125亚型将有助于提高卵巢癌诊断准确度,有望突破上述困境。CA125 is the most important serum bio- marker for the diagnosis of ovarian cancer. However, its low specificity has been the main drawback. CA125 moleeule is a huge mucin, with large amount of glycan modifications. Due to the unique glycan structures synthesized by malignant cells, CA125 molecules produced by ovarian eaneer carry glycan chains that are different from those in benign gynecological diseases. These CA125 subtypes may serve as better serum biomarkers for ovarian cancer diagnosis.

关 键 词：卵巢癌 癌抗原125 糖基化修饰 Tn-CA125 平分型-CA125 

分 类 号：R737.3[医药卫生—肿瘤]